Exploiting inflammation for therapeutic gain in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy associated with <5% 5-year survival, in which standard chemotherapeutics have limited benefit. The disease is associated with significant intra- and peritumoral inflammation and failure of protective immunosurveillance. Indeed, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Steele, C W, Jamieson, N B, Evans, T R J, McKay, C J, Sansom, O J, Morton, J P, Carter, C R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619061/
https://www.ncbi.nlm.nih.gov/pubmed/23385734
http://dx.doi.org/10.1038/bjc.2013.24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619061/
https://www.ncbi.nlm.nih.gov/pubmed/23385734
http://dx.doi.org/10.1038/bjc.2013.24

Ejemplares similares